Anivive receives $500K FDA grant for canine cancer research
by Katie Pfaff
Pet health technology company, Anivive Lifesciences Inc., has been awarded a grant from FDA for $500,000. The company will commit the funding to continued studies on canine lymphoma treatment with its LAVERDIA™ -CA1 (verdinexor) therapeutic.
Verdinexor is a small-molecule selective inhibitor of nuclear export (SINE) and received conditional FDA approval in January. The therapy is being evaluated in vitro studies of transitional cell carcinoma, osteosarcoma, histiocytic sarcoma and will begin enrollment for combination therapy in relapsed or treatment-resistant lymphoma.
The company will collaborate with Tufts University for a prospective, multisite, randomized, placebo-controlled, and double-masked pivotal trial to evaluate the safety and efficacy of verdinexor in treating lymphoma in dogs. The study will involve more than 100 canines with naïve or relapsed B- and T-cell lymphoma. "I am excited to serve as the primary investigator for this multicenter study and to build upon earlier work performed by our Associate Dean for Research, Dr. Cheryl London," said Carrie Wood, DVM, DACVIM (O), a clinical assistant professor at the Cummings School of Veterinary Medicine at Tufts University.
The funding became available under the FDA's Minor Use/Minor Species (MUMS) program, which awards grants toward the development of animal therapies for the treatment of rare or underserved diseases. Four organizations received grant funding with this round.
Comments
Related Articles
More news
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment